Eli Lilly’s Zepbound Shows Promise in Treating Sleep Apnea, Seeks FDA Approval

1. Eli Lilly's Zepbound: The weight-loss drug has demonstrated efficacy in treating moderate to severe obstructive sleep apnea in up to 52% of patients across two late-stage trials.
2. Sleep Apnea Resolution: Zepbound aided in resolving sleep apnea for 43% of patients on the drug alone and 51.5% of those concurrently using continuous positive air pressure (PAP) therapy.
3. FDA Application: Lilly has submitted an application to the U.S. FDA for Zepbound's approval in treating obstructive sleep apnea and plans to seek approvals from other regulatory bodies globally.
4. Competitive Landscape: Lilly and Novo Nordisk are both vying to expand the applications of their obesity drugs, with Novo Nordisk's Wegovy receiving approval for treating heart disease earlier this year.
5. Safety Profile: Zepbound exhibited a safety profile consistent with previous studies, with common side effects including diarrhea, nausea, vomiting, and constipation.
6. Counterfeit Concerns: Lilly has filed lawsuits against entities selling fake versions of Zepbound, warning patients about the risks of using unapproved and untested products.